Post-marketing evaluation of the safety of influenza virus vaccine live, intranasal (Flumist) in healthy children and healthy adults 5-49 years of age

Trial Profile

Post-marketing evaluation of the safety of influenza virus vaccine live, intranasal (Flumist) in healthy children and healthy adults 5-49 years of age

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2013

At a glance

  • Drugs Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jan 2013 Primary endpoints added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Planned number of patients changed from 60000 to 66438 as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Planned end date changed from 1 Sep 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top